Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immu...
INOVIQ and Promega sign a global joint marketing agreement for INOVIQ’s EXO-NET® exosome capture technology and Promega Nucleic Acid purificati...
Microba and Sonic Healthcare signed a commercial agreement to sell Microba's advanced infectious disease testing technology MetaPanel™ in Australia...
Company also issues Deferred Share Units to Board of Directors as Quarterly Director’s Remuneration Entourage Health Corp. (TSX-V: ENTG) (...
PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the resear...
New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia AstraZeneca h...
First participants have been successfully dosed in a Phase I Clinical Trial of MAP 315, Microba’s lead Therapeutic Program in Inflammatory Bo...
New data demonstrates the ability of TLX250-CDx to detect extrarenal lesions, supporting potential clinical utility in the metastatic or recurrent setting,...
The STARBURST study (ClinicalTrials.gov Identifier: NCT05563272) is a prospective, open label Phase II "basket" study to investigate CAIX expression in pat...
PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF, a biotechnology company focused on the researc...
Over the past several years, management has initiated discussions with potential strategic collaborators to provide the resources to advance PRP into clini...
New CHM 1101 (CLXT CAR T) multi-center clinical trial activated at Sarah Cannon Research Institute (SCRI) in Austin, Texas Enrolment now open to patient...
Oxley and Opie's invention, the Synchron Switch™, is an endovascular brain implant designed to record or stimulate the brain or nerves from within th...
Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP...
© 2025 Biopharma Boardroom. All Rights Reserved.
